Advances in therapeutics for neurodegenerative tauopathies: Moving toward the specific targeting of the most toxic tau species

Julia E. Gerson, Diana L. Castillo-Carranza, Rakez Kayed

    Research output: Contribution to journalReview articlepeer-review

    56 Scopus citations

    Abstract

    Neurodegenerative disease is one of the greatest health concerns today and with no effective treatment in sight, it is crucial that researchers find a safe and successful therapeutic. While neurofibrillary tangles are considered the primary tauopathy hallmark, more evidence continues to come to light to suggest that soluble, intermediate tau aggregates - tau oligomers - are the most toxic species in disease. These intermediate tau species may also be responsible for the spread of pathology, suggesting that oligomeric tau may be the best therapeutic target. Here, we summarize results for the modulation of tau by molecular chaperones, small molecules and aggregation inhibitors, post-translational modifications, immunotherapy, other techniques, and future directions. (Figure Presented).

    Original languageEnglish (US)
    Pages (from-to)752-769
    Number of pages18
    JournalACS chemical neuroscience
    Volume5
    Issue number9
    DOIs
    StatePublished - Sep 17 2014

    Keywords

    • Immunotherapy
    • Molecular chaperones
    • Oligomers
    • Small molecules

    ASJC Scopus subject areas

    • Biochemistry
    • Physiology
    • Cognitive Neuroscience
    • Cell Biology

    Fingerprint

    Dive into the research topics of 'Advances in therapeutics for neurodegenerative tauopathies: Moving toward the specific targeting of the most toxic tau species'. Together they form a unique fingerprint.

    Cite this